Jazz Pharmaceuticals plc Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

It's been a sad week for Jazz Pharmaceuticals plc (NASDAQ:JAZZ), who've watched their investment drop 14% to US$117 in the week since the company reported its annual result. The result was positive overall - although revenues of US$2.2b were in line with what analysts predicted, Jazz Pharmaceuticals surprised by delivering a statutory profit of US$9.09 per share, modestly greater than expected.